Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM
https://doi.org/10.1007/s13300-021-01042-w
Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study
https://doi.org/10.1080/03007995.2019.1647503
Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
https://doi.org/10.1007/s13340-021-00501-w
Funding for this research was provided by:
Astellas Pharma Inc.
Article History
Received: 7 December 2020
Accepted: 25 February 2021
First Online: 24 March 2021
Declarations
:
: HM received lecture fees from MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Sanofi K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Kowa Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K. and Kissei Pharmaceutical Co. Ltd.; research support from Astellas Pharma Inc., Astra Zeneca K.K., Nippon Boehringer Ingelheim Co. Ltd., Sunstar Inc., Mitsubishi Tanabe Pharma Corporation, Kyowa Hakko Kirin Co. Ltd., Nissan Chemical Corporation and MIKI Corporation; grants from Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Taisho Pharma Co. Ltd., Kowa Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Sanofi K.K., Mitsubishi Tanabe Pharma Corporation, Sanwa Kagaku Kenkyusho Co. Ltd., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Bayer Yakuhin Ltd., Teijin Pharma Limited, Shionogi & Co. Ltd., Fuji Yakuhin Co. Ltd., Pfizer Inc., MIKI Corporation, Mochida Pharmaceutical Co. Ltd., Novartis Pharma K.K. and Nipro Corporation. KT received lecture fees from MSD K.K., Novo Nordisk Pharma Ltd., Kowa Pharmaceutical Co. Ltd.; grants from Daiichi Sankyo Co. Ltd., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Teijin Pharma Limited, Eli Lilly Japan K.K., Asahi Kasei Pharma Corporation, The Mitsubishi Foundation and Suntory Global Innovation Center Ltd. IN and SU are employees of Astellas Pharma Inc.
: This study was conducted in compliance with Japanese Good Post-marketing Study Practice (GPSP) regulations. Under these regulations, informed consent was not necessary because the study involved anonymized data collected from clinical settings.
: Researchers may request access to anonymized participant level data, trial level data and protocols from Astellas sponsored clinical trials at ExternalRef removed. For the Astellas criteria on data sharing see: ExternalRef removed.